December 20, 2022
Article
The FDA will be evaluating findings from cohorts A and K from the phase 1b/2 EV-103 trial.
December 01, 2022
Article
The regimen consists of an alpha prostate-specific membrane antigen-targeted radionuclide therapy (225Ac-J591), an androgen receptor signaling inhibitor, and pembrolizumab.
November 13, 2022
Article
"We want to make sure that independent urology continues to thrive by recruiting new people to independent urology. That's what we're going to try and do," said Evan R. Goldfischer, MD.
November 11, 2022
Article
In an interview during the 2022 LUGPA Annual Meeting, Jason M. Hafron, MD, shared advice on optimizing advanced prostate cancer clinics, recapped the biggest advances in urologic cancer treatment in 2022, and discussed how Jelmyto treatment for UTUC has evolved over time.